open-label, platform trial
Prof Peter W Horby, Prof Martin, RECOVERY J Landray
doi:10.1101/2024.05.23.24307731
a randomised, controlled,
Declaration of interests The authors have no conflict of interest or financial relationships relevant to the submitted work to disclose. No form of payment was given to anyone to produce the manuscript. All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. The Nuffield Department of Population Health at the University of Oxford has a staff policy of not accepting honoraria or consultancy fees directly or indirectly from industry (see https://www.ndph.ox.ac.uk/files/about/ndph-independenceof-research-policy-jun-20.pdf).
Conflicts of interest No form of payment was given to anyone to produce the manuscript. The Nuffield Department of Population Health at the University of Oxford has a staff policy of not accepting honoraria or consultancy fees directly or indirectly from industry (see -0.68 (-1.29, -0.07) 0.03 RR=Hazard ratio for the outcomes of 28-day mortality and hospital discharge, and risk ratio for the outcome of receipt of invasive mechanical ventilation or death (and its subcomponents). CI=confidence interval. *Analyses exclude those on invasive mechanical ventilation at randomization. †Analyses exclude those on any form of ventilation at randomisation. ‡Analyses restricted to those on invasive mechanical ventilation at randomisation. §Analyses exclude those on haemodialysis or haemofiltration at randomisation.
References
Amstutz, Speich, Mentré, Effects of remdesivir in patients hospitalised with COVID-19: a systematic review and individual patient data metaanalysis of randomised controlled trials, Lancet Respir Med
Arribas, Bhagani, Lobo, Randomized Trial of Molnupiravir or Placebo in Patients Hospitalized with Covid-19, NEJM Evid
Bergeri, Whelan, Ware, Global SARS-CoV-2 seroprevalence from January 2020 to April 2022: A systematic review and meta-analysis of standardized population-based studies, PLoS Med
Bernal, Da Silva, Musungaie, Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients, N Engl J Med
Butler, Hobbs, Gbinigie, Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): an open-label, platform-adaptive randomised controlled trial, Lancet Lond Engl
Constantinides, Webster, Gentry, Rapid turnaround multiplex sequencing of SARS-CoV-2: comparing tiling amplicon protocol performance, medRxiv
Fischer, Eron, Holman, an Oral Antiviral Treatment for COVID-19
Gottlieb, Vaca, Paredes, Early Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients, N Engl J Med
Group, Horby, Mafham, Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19, N Engl J Med
Group, Horby, Peto, Dimethyl fumarate in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial, Nat Commun
Hammond, Fountaine, Yunis, Nirmatrelvir for Vaccinated or Unvaccinated Adult Outpatients with Covid-19, N Engl J Med
Hammond, Leister-Tebbe, Gardner, Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19, N Engl J Med,
doi:10.1056/NEJMoa2118542Horby, Lim, Dexamethasone in Hospitalized Patients with Covid-19, N Engl J Med
Khoo, Fitzgerald, Saunders, Molnupiravir versus placebo in unvaccinated and vaccinated patients with early SARS-CoV-2 infection in the UK (AGILE CST-2): a randomised, placebo-controlled, double-blind, phase 2 trial, Lancet Infect Dis
Liu, Pan, Zhang, Efficacy and safety of Paxlovid in severe adult patients with SARS-Cov-2 infection: a multicenter randomized controlled study, Lancet Reg Health West Pac
Owen, Allerton, Anderson, An oral SARS-CoV-2 Mpro inhibitor clinical candidate for the treatment of COVID-19, Science
Recovery Collaborative, Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial, Lancet Lond Engl
Recovery Collaborative, Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial, Lancet Lond Engl
Recovery Collaborative, Colchicine in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial, Lancet Respir Med
Recovery Collaborative, Higher dose corticosteroids in patients admitted to hospital with COVID-19 who are hypoxic but not requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial, Lancet Lond Engl
Sheahan, Sims, Zhou, An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice, Sci Transl Med
Strizki, Gaspar, Howe, Molnupiravir maintains antiviral activity against SARS-CoV-2 variants and exhibits a high barrier to the development of resistance, Antimicrob Agents Chemother
Weinreich, Sivapalasingam, Norton, REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19, N Engl J Med
Who Solidarity, Consortium, Remdesivir and three other drugs for hospitalised patients with COVID-19: final results of the WHO Solidarity randomised trial and updated meta-analyses, Lancet Lond Engl
Yoon, Toots, Lee, Orally Efficacious Broad-Spectrum Ribonucleoside Analog Inhibitor of Influenza and Respiratory Syncytial Viruses, Antimicrob Agents Chemother
